Since the publication of the above article, the authors have noticed that the red line and the blue line were accidently inverted in the annotation inside Figure 6c . Red line should indicate β-cat_low/scd1_low, while blue line should indicate β-cat_high/scd1_high.
. SCD1, YAP/TAZ and β-catenin co-expression in patients with adenocarcinoma. (a) Representative immunohistochemistry images for β-catenin, SCD1 and YAP/TAZ. In the left panel, a sample with strong expression of SCD1 (high SCD1). In the middle and right panel, intermediate and negative expression of SCD1 are shown respectively (low SCD1 and negative SCD1). Original magnification 100, inset 400). In the tumor tissue, SCD1 showed cytoplasmic and rarely nuclear staining, YAP and TAZ stained the cytoplasms and the nuclei, and β-catenin had a membranous and occasionally a granular cytoplasmic positivity. Only scattered β-catenin-positive nuclei were observed. (b) Upper panel: Kaplan-Meier curves showing the overall survival of patients expressing higher level of both scd1 and yap mRNA (scd1_high/ yap_high) or higher level of both scd1 and taz mRNA (scd1_high/taz_high) compared with patients having the two genes not correlated (other). Lower panel: similar analysis was performed to analyze the overall survival of patients expressing higher level of scd1 and ctgf (scd1_high/ctgf_high) or scd1 and birc5 (scd1_high/birc5_high). (c) Kaplan-Meier curves showing the overall survival of patients with scd1 and β-catenin mRNA at higher level compared with patients showing lower scd1 and β-catenin mRNA level. (d) Kaplan-Meier curves showing the overall survival of patients with tumor recurrence. Analysis was carried out in patients with scd1 and β-catenin mRNA both at higher level compared with patients showing lower scd1 and β-catenin mRNA.
